⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
Global CD70-Targeting Therapies Market Report 2026 - Highlights Clinical Innovation, Pipeline Trends and Commercial Opportunities
globenewswire.com
ALLO
CRSP
JNJ
PFE
ADCT
REGN
MRNA
BMY
GILD
AMGN
BIIB
AZN
NVS
LLY
ABBV
ITOC Stockholders Have Rights – If You Lost Money Investing in iTonic Holdings Ltd. Contact Robbins LLP for Information About Recovering Your Losses
businesswire.com
PTHL
ITOC
GILD
Workato Launches Otto for Everyone, AI Superagents That Run Whole Projects Start to Finish
businesswire.com
AMZN
CSCO
NVDA
GOOG
MSFT
IBM
ORCL
CRM
INTC
AMD
MU
QCOM
AAPL
META
NFLX
GOOGL
AMPL
SPCE
TSLA
BNTX
CRSP
EDIT
GILD
MRNA
REGN
VRTX
BIIB
AMGN
NCLH
CCL
RCL
XOM
CVX
SHEL
T
VZ
TMUS
NKE
DIS
MCD
KO
PEP
WMT
HD
JNJ
PG
UNH
MA
V
BOX
SHOP
Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma
prnewswire.com
GILD
GSK
Blood Cancer Therapeutics Market to Reach $125.5 Billion by 2030, Driven by Precision Medicine Advances and Expanding Immunotherapy Pipelines
globenewswire.com
ABBV
AMGN
AZN
BMY
ROG
GILD
GSK
JNJ
LLY
MRK
NVS
SNY
PFE
JAZZ
AMRX
Keymed Biosciences anuncia los resultados del primer semestre de 2026 y novedades empresariales
prnewswire.com
AZN
GILD
Keymed Biosciences gibt Ergebnisse für das erste Halbjahr 2026 sowie aktuelle Geschäftsentwicklungen bekannt
prnewswire.com
AZN
GILD
Keymed Biosciences annonce ses résultats pour le premier semestre 2026 et fait le point sur ses activités
prnewswire.com
GILD
AZN
Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight
globenewswire.com
BIIB
HRMY
XNCR
AZN
LLY
PFE
REGN
NVS
TSLA
TAK
GSK
JNJ
UCB
BHF
PRAX
XENE
AQST
TNDM
INCY
MRK
ABBV
BMY
AMGN
GILD
VRTX
CRSP
EDIT
NTLA
SRPT
ALNY
EXAS
TEVA
AXSM
CYTK
INSM
KODK
LPCN
MNKD
NBIX
NCLH
ONCY
ORIC
PBYI
PEGA
PLRX
PRGS
QGEN
RGNX
ROST
RYAAY
SNOW
SWKS
SYK
TGT
TRMB
TXG
ULTA
VRSK
WDC
WVE
XOM
ZBRA
ZNTL
ZTS
STOK
IONS
MOMO
BBAR
CTXR
MBIO
GNS
NEON
OVID
BHVN
Amplifica Appoints Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to Board of Directors
prnewswire.com
ACRS
ALC
AMGN
BCRX
BIIB
BMY
CRSP
CTRA
CYTK
DASH
EXAS
GILD
GSK
INCY
JNJ
KDP
LULU
MRNA
NBIX
NVS
OCGN
ORCL
PFE
REGN
ROST
RVMD
SNOW
SRPT
STRL
TGTX
TMO
TRMB
TSLA
TXG
VRTX
XOM
ZBRA